SHYNDEC(SH:600420) Xin Lang Cai Jing·2025-11-03 09:03Core Viewpoint - The announcement indicates that China National Pharmaceutical Group's subsidiary, Guoyao Zhijun (Pingshan) Pharmaceutical Co., Ltd., has signed a drug listing license transfer contract with Anhui Meilai Pharmaceutical Co., Ltd. for the product Lactulose Oral Solution, which will enhance the company's product line in chronic disease treatment and strengthen its market competitiveness [1] Summary by Relevant Categories Transaction Details - The total transfer fee for the drug listing license is RMB 5.86 million [1] - The product involved in the transfer is Lactulose Oral Solution (15ml:10g) [1] Strategic Implications - The transaction aligns with the company's strategic development plan [1] - It is expected to enrich the company's product line for chronic disease treatment [1] - The deal is anticipated to enhance the market competitiveness of Guoyao Zhijun Pingshan [1] Financial Impact - The transaction will not have a significant impact on the company's current operating performance [1]